STOCK TITAN
  1. Home
  2. SEC-Filings
  3. BCAX

Bicara Therapeutics SEC Filings

BCAX NASDAQ

Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Clinical trial read-outs, shelf registrations, and sudden capital raises make Bicara Therapeutics’ SEC disclosures anything but straightforward. If you have ever searched a 300-page prospectus just to find cash-runway details, you know the challenge.

Our platform solves that problem. Stock Titan’s AI instantly converts dense language into plain-English highlights, letting you understand Bicara Therapeutics SEC documents with AI instead of slogging through technical jargon. Need the latest 8-K material events explained or the most recent Bicara Therapeutics quarterly earnings report 10-Q filing? Every form appears here in real time, tagged and summarized.

Here’s how analysts, portfolio managers, and biotech followers use this page:

  • Track Bicara Therapeutics insider trading Form 4 transactions and receive alerts on executive stock transactions Form 4 moments after they hit EDGAR.
  • Compare R&D spend, dilution risk, and cash burn with our AI-layered Bicara Therapeutics annual report 10-K simplified notes.
  • Dive into pipeline progress via Bicara Therapeutics 8-K material events explained, including interim data disclosures for ficerafusp alfa.
  • Review compensation packages through the Bicara Therapeutics proxy statement executive compensation section without hunting across exhibits.

Whether you’re screening biotech investments or verifying a single clinical milestone, our comprehensive coverage—10-K, 10-Q, S-1, 8-K, and Bicara Therapeutics Form 4 insider transactions real-time—keeps you ahead of market-moving details. No more page-count anxiety; the insights you need are surfaced instantly, ready for decisive action.

Filing

[Form 4] Bicara Therapeutics Inc. Insider Trading Activity

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Bicara Therapeutics (BCAX)?

The current stock price of Bicara Therapeutics (BCAX) is $8.71 as of June 28, 2025.

What is the market cap of Bicara Therapeutics (BCAX)?

The market cap of Bicara Therapeutics (BCAX) is approximately 500.6M.

What is the primary focus of Bicara Therapeutics?

Bicara Therapeutics is dedicated to the development of bifunctional antibody therapies that target both EGFR and TGF-β, primarily to address the treatment needs in patients with solid tumors.

How does ficerafusp alfa work?

Ficerafusp alfa is designed to block two critical signaling pathways—EGFR, which is essential for cancer cell survival and proliferation, and TGF-β, which contributes to immunosuppression in the tumor microenvironment. This dual mechanism aims to enhance anti-tumor activity.

In which therapeutic areas is Bicara Therapeutics involved?

The company focuses on oncological indications, with particular attention to head and neck squamous cell carcinoma and other solid tumor types where traditional therapies have not fully met medical needs.

What distinguishes Bicara’s approach in oncology?

Bicara Therapeutics employs a bifunctional antibody strategy, combining two clinically validated targets into one therapeutic agent. This method is distinct because it simultaneously disrupts tumor proliferation and mitigates the immunosuppressive environment.

How does the company ensure scientific rigor in its research?

Bicara Therapeutics adheres to stringent clinical trial methodologies, incorporating robust preclinical data and iterative clinical studies to validate the efficacy and safety of its therapeutic approaches.

What role does the tumor microenvironment play in the company’s research?

The tumor microenvironment is crucial because it not only supports cancer cell growth but also contributes to resistance against treatments. By targeting TGF-β, Bicara aims to modulate this environment and foster conditions more favorable to immune system engagement.

How does Bicara Therapeutics position itself in the competitive oncology landscape?

The company differentiates itself through its innovative bifunctional antibody mechanism and data-driven clinical trial designs, positioning itself as a thoughtful and methodical participant in the development of new oncological therapies.

What are the main benefits of the dual-targeting approach?

The dual-targeting approach enables simultaneous disruption of critical pathways involved in tumor survival and immunosuppression, potentially leading to improved anti-tumor activity and enhanced therapeutic outcomes for patients.
Stock BCAX logo
Bicara Therapeutics

NASDAQ:BCAX

BCAX Rankings

#3133 Ranked by Market Cap
N/A Ranked by Dividends

BCAX Stock Data

500.64M
43.93M
0.43%
86.05%
10.31%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE